Tag: Clostridium difficile

Fulminant Clostridium difficile colitis (FCDC) is a major complication of C. difficile colitis that has not responded to non-invasive interventions, and is ultimately treated with laparotomy, total abdominal colectomy (TAC), and end-ileostomy. Diverting loop ileostomy and colonic lavage, however, represents another surgical option in the management of FCDC, with...
2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: long-term follow-up of a multicentre, randomised trial The ideal surgical excision margin for patients with thick (>2 mm) localized cutaneous melanomas is unclear, where the risk of recurrence must be weighed against excess morbidity resulting from...
Several recently published guidelines regarding the treatment of C. difficile infection recommend vancomycin as first-line antibiotic treatment. However, given the recent increase in severity and frequency of C. difficile infections, there is a critical need for novel C. difficile therapies. Cadazolid is a novel quinoxolidinone antibiotic that acts in...
Impact of scribes on emergency medicine doctors’ productivity and patient throughput: multicentre randomised trial Medical scribes are used in variety of clinical settings to complete clerical tasks otherwise done by a clinician. Limited research has been done concerning the effects of scribes on physician productivity in emergency medicine settings. In...
1. Multiply recurrent Clostridium difficile infection (mrCDI) incidence has increased disproportionately to Clostridium difficile infection (CDI), independent of known risk factors for CDI. 2. There is a rising demand for mrCDI therapies in the future. Evidence Rating Level: 2 (Good) Study Rundown: CDI is a significant health concern. Not only is CDI a...
1. In this systematic review and meta-analysis of observational data, gastric acid suppression was associated with increased risk of recurrent Clostridium difficile infection (CDI). 2. Gastric acid suppression’s link with recurrent CDI was observed in subgroup analysis of studies that examined only proton-pump inhibitors, but not in studies that included...
1. In this retrospective cohort study, clinical outcomes and recurrence rates of mild to moderate Clostridium difficile infection (CDI) were similar among patients initially treated with metronidazole versus vancomycin. 2. Among patients with severe CDI, 30-day mortality risk was significantly decreased among those initially treated with vancomycin, further adding to...
1. Bezlotoxumab therapy associated with significantly lower rate of recurrent C. difficile infection compared to placebo. 2. Actoxumab not efficacious when administered aloine or in combination with bezlotoxumab in reducing rates of recurrent C. difficile infection. Evidence Rating Level: 1 (excellent) Study Rundown: In hospitalized patients, C. difficile is a widespread...
1. Screening for and isolating carriers of Clostridium difficile at admission to hospital was associated with lower rates of healthcare-associated C. difficile infection (HA-CDI) at a single institution in Quebec, CA. 2. A multi-center study would be needed to identify the effectiveness of this strategy in a broader population. Evidence Rating...
  1. Chemical screening showed that ebselem, a small molecule currently in clinical trials for unrelated usclostres, inhibited the cysteine protease domain (CPD) of toxins A (TcdA) and B (TcdB) produced by Clostridium difficile (C. diff). 2. In two murine models of C. diff infection, treatment with ebselem led to increased...